

cyte catalase from either source can be noticed. Normal catalase retained as much as 50% of its original activity after preincubation at 64°C, whereas – under identical conditions – complete inactivation had occurred in the acatalasemic leukocyte preparation. In this instance, the 50% activity level was reached after incubation at 51°C already. Immunological antigenic properties of normal leukocyte catalase have been compared with those of erythrocyte catalase in the double immunodiffusion test (Figure 2). A strong precipitin line showing complete identity is formed between the wells containing the preparations of normal leukocytes, normal erythrocytes and anti-catalase IgG (Figure 2, right side). This line exhibits strong peroxidatic activity (Figure 2, left side). A second, as yet unidentified weaker line exerting no peroxidatic activity is precipitated in the range of the leukocyte preparation only. Experiments of the same type performed with analogous preparations from A.B. suggest that there is also antigenic identity between normal and acatalasemic leukocyte catalase.

Discussion. Evidence is presented that leukocytes of an acatalasemic subject (homozygous for Swiss Type Acatalasemia) contain appreciable amounts of catalase. In A.B. the level corresponds to about $\frac{1}{7}$ of that of normal, which is distinctly higher than that found in the

erythrocytes of the same individual (1–2% of normal). Like the mutant enzyme in the erythrocytes¹, its antigenically identical counterpart in leukocytes also exerts the same unusually low degree of thermostability. This observation is compatible with the assumption that, in an enzyme deficiency, two different types of structural gene mutations may lead to an apparent loss of enzymatic activity: 1. Enzyme variants of low specific activity, 2. variants with approximately normal specific activity, but of low stability. Eventually, both possibilities may lead to the same type of disorder. Examples are the different forms of glucose-6-phosphate-dehydrogenase-deficiency or of acatalasemia^{1,10}. In the unstable mutant-type, the low level of residual activity in red blood cells must be considered as a poor indicator for the general situation, since in most other cells and tissues distinctly higher levels are found. In conclusion, there is a close analogy as to catalase stability and activity distribution pattern between acatalasemic mice and individuals homozygous for this particular type of acatalasemia^{11,12}.

Zusammenfassung. Beim Akatalasie-Fall A.B. ist die in den Leukozyten vorhandene Katalase-Restaktivität wesentlich höher (13%) als diejenige in den Erythrozyten (etwa 1% der Norm), wie dies beim Vorliegen einer instabilen Enzymvariante zu erwarten ist. Die Enzyme beider Zelltypen sind antigen-identisch und zeigen denselben Grad von Thermolabilität.

SONJA R. WYSS and H. AEBI

Catalase activity in leukocytes and erythrocytes of normal and acatalasemic humans (Family B.)

Material analyzed		Catalase activity
Leukocytes	Normal (N = 15)	3.09 ± 0.73 µg/mg Protein
	Acatalasemic (N = 2)	0.41 (= 13% of normal)
Erythrocytes	Normal (N = 15)	2.38 ± 0.36 µg/mg Hb
	Acatalasemic (N = 2)	0.02 (~1% of normal)

Medizinisch-chemisches Institut der Universität,
CH-3000 Bern 9 (Switzerland), 4 April 1974.

¹⁰ H. AEBI, Verh. dt. Ges. inn. Med. 78, 304 (1972).

¹¹ H. AEBI, H. SUTER and R.N. FEINSTEIN, Biochem. Genet. 2, 245 (1968).

¹² Acknowledgments. This study is part of project No. 3.8460.72 subsidized by the Swiss National Science Foundation. We are grateful to Dr. E. SHAPIRA for providing us with anti-catalase IgG and to Dr. F. SKVARIL for helpful criticism.

The Detection of 5 α -Androst-16-en-3 α -ol in Human Male Axillary Sweat

The 16-dehydro C₁₉ steroid 5 α -androst-16-en-3 α -ol (androst-16-en-3 α -ol) is excreted in the urine of adult human males in substantial quantities (of the order of 1 mg/24 h urine) and in lesser amounts in adult female urine¹. The physiological function, if any, of the 16-dehydro C₁₉ steroids in man is unknown, but androst-16-en-3 α -ol secreted in the saliva of the boar acts as a releaser sex pheromone in eliciting the characteristic immobilization response of the oestrous sow to the advances of its mate^{2–4}.

There are, however, circumstantial grounds for believing that pheromones may play a part in human behaviour^{5,6}. Androst-16-en-3 α -ol, which has a musk-like odour detectable by human subjects at extremely low levels (1–5 ng on water at 20°C, 10 cm from the nose; BROOKSBANK, unpublished) is a likely candidate as a pheromone in man, though various other steroids can be smelt at much higher concentration⁷. External secretion, onto the skin surface, would be the most probable way in which human pheromones are exhibited. In view of the evident capacity of axillary glands and hairs for preferential uptake and release of steroids^{8,9} and the similarity of axillary apocrine glands in morphology and in androgen-dependence to apocrine glands specialized in lower mammals for pheromone secretion^{10–12}, we believed that axillary sweat might contain sufficient quantities of 16-dehydro C₁₉ steroids to be detectable by gas chromatography-mass spectrometry (GC/MS). Previous efforts, using GC alone

dence to apocrine glands specialized in lower mammals for pheromone secretion^{10–12}, we believed that axillary sweat might contain sufficient quantities of 16-dehydro C₁₉ steroids to be detectable by gas chromatography-mass spectrometry (GC/MS). Previous efforts, using GC alone

¹ B. W. L. BROOKSBANK, J. Endocr. 24, 435 (1962).

² R. L. S. PATTERSON, J. Sci. Fd. Agric. 19, 434 (1968).

³ D. R. MELROSE, H. C. B. REED and R. L. S. PATTERSON, Br. vet. J. 127, 497 (1971).

⁴ D. B. GOWER, J. Steroid Biochem. 3, 45 (1972).

⁵ H. WIENER, New York State J. Med. 66, 3153 (1966).

⁶ A. COMFORT, Nature, Lond. 230, 432 (1971).

⁷ J. KLOEK, Psychiat. Neurol. Neurochir. 64, 309 (1961).

⁸ M. JULESZ, Acta med. hung. 25, 273 (1968).

⁹ B. W. L. BROOKSBANK, Experientia 26, 1012 (1970).

¹⁰ H. J. HURLEY and W. B. SHELLEY, *The Human Apocrine Sweat Gland in Health and Disease* (Charles C. Thomas, Springfield, Illinois 1960).

¹¹ W. MONTAGNA, *The Structure and Function of Skin*, 2nd edn. (Academic Press, New York and London 1962).

¹² J. E. STRAUSS and F. J. EBLING, Mem. Soc. Endocr. 18, 341 (1970).


without internal checks on recovery (BROOKSBANK and CUNNINGHAM, unpublished), to detect these steroids in human axillary sweat had been unsuccessful, but GOWER and LLEWELLYN (see⁴) had detected 5 α -androst-16-en-3-one (androst-16-en-3-one).

Axillary sweat was collected on defatted cotton-wool pads worn in the armpits by 12 healthy young men over a period of 5–7 days. The pads were exhaustively extracted with acetone followed by methanol, in the presence of a tracer quantity (2.4 ng) of 4,16-[7 α -³H] androstadien-3-one (androstadienone) (4.0 Ci/mmol). The soluble residue from the extractions was partitioned between water and benzene to furnish an oily extract ('sebum'¹³; 620 mg) containing unconjugated steroids, and an extract ('sulphated steroids') containing steroids excreted as sulphate conjugates that were recovered by acid solvolysis in ethyl acetate. The 'free steroid' fraction was redissolved in the minimum volume of hot methanol, and the material that precipitated on refrigeration overnight was removed; this cold methanol precipitation step was repeated. The methanol-soluble residue was taken up in benzene and free fatty acids were removed by washing the benzene solution with M.NaOH and with water. The neutral lipid material remaining, and the neutral extract obtained directly from solvolysis of the 'sulphated steroid' extract, were then separately chromatographed on alumina columns; additional tracers of [7 α -³H]androst-16-en-3-one (0.6 ng) and of [4-¹⁴C]cholesterol being added at this stage. Fractions containing ³H-androst-16-en-3-one, ³H-androstadienone (marker for androst-16-en-3-one) and ¹⁴C-cholesterol (marker for 5 α -androst-16-en-3-one) were obtained by elution (cf.⁴) with light petroleum-benzene (9:1) followed by light petroleum-benzene (1:1). The column fractions were subjected to thin-layer chromatography (TLC) on silica gel in toluene-ethyl acetate (19:1 for the androst-16-en-3-one fraction; 9:1 for the other fractions).

Examination by GC on 3% QF-1 at 200° ('androst-16-en-3-one' fractions run underivatized, other fractions after reaction with chloromethyltrimethylsilyl (CMDMS) ether reagent¹⁴) of the fractions recovered from the TLC plates showed that some androst-16-en-3-one might be present in the free steroid extract but that further purification of the

androst-16-en-3-one and 3 β -androst-16-en-3-one fractions was necessary. This was carried out on alumina columns after hydrolysis of the CMDMS ethers (0.02 M HCl in 25% aqueous ethanol at 60° for 30 min), using the same solvent systems for elution as before. Analysis by GC on 3% QF-1 and 3% OV-1 columns at 195° and without formation of derivatives, showed that androst-16-en-3-one might be present in the appropriate fractions derived from the 'free steroid' extract. The small remainder of the purified fractions from the 'free steroid' and 'sulphate conjugate' extracts of sweat were therefore subjected to GC/MS, after reaction with trimethylsilyl (TMS) ether reagent, on a 1% SE-30 column incorporated in an LKB-9000 GC/MS system. Mass spectra, taken at 6 sec intervals, were analyzed in an IBM 1800 computer¹⁵. The presence of androst-16-en-3-one in the 'free steroid' extract of axillary sweat was shown by the occurrence in the 'androst-16-en-3-one' fraction of a peak with the relative retention time (t_R) (with respect to 5 α -cholestane) of 5 α -androst-16-en-3-one TMS ether ($t_R = 0.16$) with the fragmentation pattern characteristic of the authentic compound (Figure). No androst-16-en-3-one was detected in the corresponding fraction from the sweat 'sulphate conjugate' extract, nor was any androst-16-en-3-one detected in either extract.

The quantity of androst-16-en-3-one in the sweat 'free steroid' extract can only be estimated very roughly from the peak heights in the final GC chromatograms as no attempt at quantitative measurement was made. Allowing for the manipulation losses, assessed from the recovery of ³H-androstadienone – which was not separated from androst-16-en-3-one except on GC –, there was about 4 μ g of androst-16-en-3-one in the original 620 mg of sebum derived from the axillae of 12 adult men, that is from an area of approximately 300 cm² per day for about 6 days. Thus, androst-16-en-3-one, and probably also androst-16-en-3-one⁴, do occur in axillary sweat from adult men. If they are significant as pheromones the excretion is almost certain to vary enormously between and within individuals and the amounts we have found are large enough to be consistent with a pheromonal function. However, the demonstration of a pheromonal function of any steroid in man remains to be made by other methods.



Mass spectra of authentic (a) and isolated (b) 5 α -androst-16-en-3-one TMS ethers. The base peak in (b) (m/e 57) is formed from contaminating material with the same t_R as 5 α -androst-16-en-3-one TMS ether; this explains the lower relative intensities of the peaks at m/e 346 (molecular ion, M), 331 (M-15), 256 (M-90) and 241 (M-(90 + 15)) in the mass spectrum of the isolated steroid when compared to that of the authentic compound.

Résumé. La présence du 5 α -androstène-16-3 α -ol d'odeur musquée dans la fraction contenant les stéroïdes libres de la sueur des aisselles, recueillie chez des hommes sains adultes, a été établie par chromatographie en gaz avec spectrométrie de masse. La quantité d'androst-16-en-3-one trouvée n'exclut pas la possibilité d'une fonction phéromonale de ce stéroïde.

B.W.L. BROOKSBANK, R. BROWN and J.-A. GUSTAFSSON¹⁶

Medical Research Council Neuropsychiatry Unit, Woodmansterne Road, Carshalton, Surrey (England), and Department of Chemistry, Karolinska Institutet, Stockholm (Sweden), 11 March 1974.

¹³ R. M. B. MCKENNA, V. R. WHEATLEY and A. WORMALL, J. invest. Derm. 15, 33 (1950).

¹⁴ B. W. L. BROOKSBANK and D. B. GOWER, Acta endocr., Copenh. 63, 79 (1970).

¹⁵ R. REIMENDAL and J. SJOVALL, Analyt. Chem. 45, 1083 (1973).

¹⁶ We acknowledge with grateful thanks gifts of [³H]-androst-16-en-3-one and [³H]-androstadienone by Dr. D. B. GOWER, Guy's Hospital Medical School, London. This investigation was, in part, financed by a grant from the Swedish Medical Research Council No. 13X-2819.